TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT04411043

Observatory of Prolymphocytic Leukemia T

ClinicalTrials.gov

Plain-language summary

This trial is testing CD7-targeted CAR-T cell therapy for patients with T-cell prolymphocytic leukemia (T-PLL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Molecular caracterization (BEHAVIORAL): Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T

  • Molecular caracterization

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is T-PLL?

Plain-language overview of T-PLL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Observatory of Prolymphocytic Leukemia T

NCT04411043

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing CD7-targeted CAR-T cell therapy for patients with T-cell prolymphocytic leukemia (T-PLL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Molecular caracterization (BEHAVIORAL): Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T

Drugs / treatments: Molecular caracterization

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 50 patients

Primary endpoint: Clinical characteristics of prolymphocytic leukemia T; Biological characteristics of prolymphocytic leukemia T; Flow cytometry data of bone marrow and blood cells; karyotype of tumor cells

Ages: 18 Years to —

Start date: 2020-07-01 | Est. completion: 2028-07-30

Locations

0 US sites · 1 total

Contact

Charles HERBAUX, Dr | Charles.herbaux@chru-lille.fr | 3 20 44 57 13

Sponsor: French Innovative Leukemia Organisation (OTHER)

Tags

T-PLL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04411043

Prepared using TrialCompass (trialcompass.com) on August 2, 2026. For informational purposes only. Always discuss with your healthcare team.